Below is a full list of the new generics added to the 2020 Medicare Part D (PDP) and Medicare Advantage plan (MAPD) formularies:
|
|
Number of |
Number of |
| CEFDINIR 250 MG/5 ML ORAL SUSPENSION [Omnicef] | 69 | 391 |
| DEFERASIROX 180 MG TABLET [Jadenu] | 51 | 333 |
| DEXABLISS 11 DAY 1.5 MG TABLET DS PK [ZCORT] | 1 | 9 |
| DICLOFENAC EPOLAMINE 1.3% PATCH TD12 [Licart] | 2 | 114 |
| DVORAH 325-30-16 MG TABLET [Panlor] | 0 | 7 |
| METHYLPHENIDATE ER 10 MG CAPSULE CSBP 40-60 [Ritalin LA] | 1 | 35 |
| METHYLPHENIDATE ER 15 MG CAPSULE CSBP 40-60 [Aptensio XR] | 1 | 35 |
| METHYLPHENIDATE ER 20 MG CAPSULE CSBP 40-60 [Ritalin LA] | 1 | 34 |
| METHYLPHENIDATE ER 30 MG CAPSULE CSBP 40-60 [Ritalin LA] | 1 | 34 |
| METHYLPHENIDATE ER 40 MG CAPSULE CSBP 40-60 [Ritalin LA] | 1 | 34 |
| METHYLPHENIDATE ER 50 MG CAPSULE CSBP 40-60 [Metadate CD] | 1 | 35 |
| METHYLPHENIDATE ER 60 MG CAPSULE CSBP 40-60 [Ritalin LA] | 1 | 35 |
| METHYLPHENIDATE LA 20 MG CAPSULE CPBP 50-50 [Ritalin LA] | 9 | 187 |
| METHYLPHENIDATE LA 30 MG CAPSULE CPBP 50-50 [Ritalin LA] | 9 | 186 |
| MICAFUNGIN 100 MG VIAL [Mycamine] | 46 | 303 |
| MICAFUNGIN 50 MG VIAL [Mycamine] | 46 | 301 |
| NALOXONE 2 MG AUTO-INJECTOR[EVZIO] | 2 | 18 |
| NITISINONE 10 MG CAPSULE [Orfadin] | 68 | 368 |
| NITISINONE 2 MG CAPSULE [Orfadin] | 68 | 368 |
| NITISINONE 5 MG CAPSULE [Orfadin] | 68 | 368 |
| NIZATIDINE 150 MG CAPSULE [Axid] | 47 | 334 |
| NIZATIDINE 300 MG CAPSULE [Axid] | 47 | 335 |
| POTASSIUM CL 20 MEQ-0.45% NACL IV SOLN | 63 | 359 |
| POTASSIUM CL 40 MEQ/100 ML SOL PIGGYBACK | 42 | 286 |
| RANOLAZINE ER 1,000 MG TABLET 12H [Ranexa] | 69 | 390 |
| RANOLAZINE ER 500 MG TABLET 12H [Ranexa] | 69 | 390 |
| TERIPARATIDE 620 MCG/2.48 ML PEN INJECTOR [Forteo] | 13 | 165 |
| VENLAFAXINE HCL 100 MG TABLET [Effexor] | 69 | 393 |
| VENLAFAXINE HCL 25 MG TABLET [Effexor] | 69 | 393 |
| VENLAFAXINE HCL 37.5 MG TABLET [Effexor] | 69 | 393 |
| VENLAFAXINE HCL 50 MG TABLET [Effexor] | 69 | 393 |
| VENLAFAXINE HCL 75 MG TABLET [Effexor] | 69 | 393 |
| VTOL LQ 50-325-40 MG/15 ML SOLUTION | 1 | 16 |
| ZIPRASIDONE 20 MG/ML VIAL [Geodon] | 69 | 387 |
What Could the Addition of New Generic Drugs Mean to You?
- You may be able to save money by switching
from the brand-name drug to its generic equivalent – with your prescriber’s
approval and a new prescription. Please note, you will need to look
carefully at coverage costs as we have found that many 2020 generics are being
offered on the same tier as their brand-name equivalent or the generics do not
have a significantly lower retail price.
- Your brand-name drug may no longer be
available if a generic is now available. Based on past
experience, you may find that many Medicare Part D plans discontinue
coverage for the brand-name drug in the months following the
introduction of the generic equivalent - or your plan may immediately drop the brand-name drug now that the generic is being introduced
.
If you have received notice from your Medicare Part D plan that your brand-name medication will be dropped, you should speak with your prescriber to determine if you can take the generic equivalent or if you must continue taking the brand-name drug, you will need to ask your plan for a formulary exception to continue coverage for your brand-name drug.
You can click for a chart showing the trends in formulary coverage for some of the more popular Medicare drugs and their generic equivalents.